BioSpace News Archive

Nurix Therapeutics, Inc. announced that it has entered into a securities purchase agreement with an institutional investor to sell, in a registered direct offering, pre-funded warrants to purchase 3,945,480 shares of common stock at a price of $13.939 per pre-funded warrant for total gross proceeds of approximately $55 million, before deducting estimated offering expenses.

A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer is now approved by the Food and Drug Administration of the Philippines.

Cyclophilin Inhibitors Therapeutics Market provides details about the market dynamics affecting the Cyclophilin Inhibitors Therapeutics market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Medical Display Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Medical Display market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Exelixis, Inc. and Ryvu Therapeutics S.A. announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu’s STING technology.

SPEXIS AG, a clinical-stage biopharmaceutical company, announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone in a metastatic prostate cancer preclinical model.

Genespire, a next generation gene therapy company developing first-in-class transformative therapies with advanced lentiviral vectors, today announces the appointment of Dr. Sabah Sallah MD, PhD as Chief Medical Officer.

The oversubscribed first close of Series B funding was led by Cathay Health, joined by Credit Mutuel Innovation, Kurma Partners and BNP Paribas Développement.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Advancements in the field of nanotechnology and soaring need for metal nanoparticles across various end-use industries are likely to significantly rub off on demand for gold nanoparticles.

Fact.MR’s recent study published on the global diabetes management software market provides detailed insights into prominent aspects favoring growth between 2022 and 2032.